{"url":"https://newsforagent.com/news/2026-10-15/scibase-eis-nih-threat-study-endpoint","markdown_url":"https://newsforagent.com/news/2026-10-15/scibase-eis-nih-threat-study-endpoint.md","title":"SciBase EIS Picked as NIH Skin Study Endpoint","headline":"SciBase's Nevisense EIS Technology Chosen as Primary Endpoint in NIH-Led THREAT Skin Study","description":"SciBase's Nevisense EIS technology will serve as the primary endpoint in an NIH-led THREAT study of 80 healthy volunteers exposed to SLS products and synthetic fibers.","section":"Research & Clinical Trials","published_at":"2026-10-15T06:53:35+00:00","modified_at":"2026-10-15T06:53:35+00:00","author":"News Desk","key_takeaways":["SciBase's Nevisense and its Electrical Impedance Spectroscopy technology will be the primary endpoint in the NIH-led THREAT study.","The study involves 80 healthy volunteers exposed to SLS-containing products, synthetic fibers, or 100% cotton.","SciBase CEO Pia Renaudin said the selection highlights the scientific relevance of EIS in assessing skin barrier function."],"companies":[{"name":"SciBase","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00022jj/scibase","website":"https://scibase.com"},{"name":"NIH Funding","is_primary":false,"profile_url":"https://akta.pro/company-profiles/004io88/nih-funding","website":"https://grants.nih.gov"}],"source":{"publisher":"PR Newswire","title":"SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Study","url":"https://www.prnewswire.com/news-releases/scibases-eis-technology-selected-as-primary-endpoint-in-nih-skin-barrier-study-302909610.html"},"other_sources":[],"tags":["Research & Clinical Trials","SciBase","NIH Funding"],"body_markdown":"[SciBase](https://akta.pro/company-profiles/00022jj/scibase) Holding AB said its Nevisense Electrical Impedance Spectroscopy technology will be the primary endpoint in an [NIH](https://akta.pro/company-profiles/004io88/nih-funding)-led study of how environmental exposures affect the skin. The study, called THREAT, involves 80 healthy volunteers and is a collaboration between the NIH and the Swiss Institute of Allergy and Asthma Research, [PR Newswire](https://www.prnewswire.com/news-releases/scibases-eis-technology-selected-as-primary-endpoint-in-nih-skin-barrier-study-302909610.html) reported on October 15, 2026.\n\n## How the THREAT Study Will Use EIS\n\nIn the THREAT study, Testing Harms Related to Exposure to Allergenic Toxins, healthy subjects will be exposed to common skin products containing sodium lauryl sulfate, bedding and clothing made of synthetic fibers, or pure contactants free of SLS and apparel and linen made from 100% cotton. The effects will be measured and compared using skin impedance as a marker of skin barrier dysfunction. Skin impedance devices transmit electrical signals at different frequencies that sense opposition to the electrical flow, reflecting the barrier functional status of the skin.\n\nEIS will monitor changes in skin barrier function over time alongside molecular, microbiome and inflammatory biomarkers. The study design was described in an editorial in the peer-reviewed journal Allergy titled \"Exploring the Link Between Environmental Exposures and Disease via Direct Challenge.\" The NIH has funded research into environmental and occupational health risks, including a $3.7 million study at the University of Colorado Boulder examining airborne mold and allergens in cannabis facilities, [Yahoo](https://akta.pro/news-signals) reported on October 1, 2026.\n\n\"We are pleased that our Nevisense technology has been selected for this important NIH-led research initiative,\" said Pia Renaudin, CEO of SciBase. \"The use of skin impedance as a primary endpoint highlights the scientific relevance of EIS in assessing skin barrier function.\"\n\n## SciBase's Clinical and Regulatory Record\n\nSciBase is a Swedish medical technology company that develops and commercializes Nevisense, an FDA-approved and CE-marked Electrical Impedance Spectroscopy device for melanoma detection and atopic dermatitis assessment, according to [akta.pro company records](https://akta.pro/company-data). The company has sold over 400,000 tests globally. In June 2026, SciBase launched the DETECT-AD multicenter prospective clinical study with Castle Biosciences to assess EIS technology's ability to predict atopic dermatitis flares. In March 2026, the FDA approved extended labeling of Nevisense to allow physician assistants and medical assistants to perform the procedure.\n\n## Earlier SciBase Developments\n\nSciBase reported a net loss of TSEK 53,383 for the first half of 2026 despite a 68% increase in net sales to TSEK 29,586, PR Newswire reported on August 19, 2026. The company also submitted a premarket notification to the U.S. On September 3, 2026, SciBase decided to carry out a new share issuance of approximately 57.5 million Swedish kronor with pre-emptive rights for existing shareholders, Dagens industri reported. On October 7, 2026, SciBase recalculated its series TO 2 warrants after a September 3, 2026 rights issue, with each warrant entitling the holder to subscribe for 0.01 shares at SEK 37.47 per share, exercisable from April 3 to April 17, 2029, PR Newswire reported.\n\n## What Comes Next for SciBase\n\nCEO Pia Renaudin will leave her role effective December 31, 2026, after nearly three years with the company, PR Newswire reported on July 28, 2026. The THREAT study results may inform dermatology and cosmetic research.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}